Oragenics, Inc. Form 8-K Summary
Business Context and Reporting Period
Oragenics, Inc. (a Florida corporation) filed this Current Report on Form 8-K on April 6, 2018, to disclose the entry into a Material Definitive Agreement. The report details a capital raise transaction that closed on April 10, 2018.
Key Financial Metrics
- Gross Proceeds: Approximately $1,800,000 from the sale of 900,000 shares of common stock at $2.00 per share.
- Placement Agent Fee: 8% of gross proceeds paid in cash to Ladenburg Thalmann & Co. Inc.
- Warrants Issued: 900,000 warrants exercisable for one share of common stock each at an exercise price of $2.00 per share.
- Warrant Terms: Exercisable beginning six months after issuance; expire five years after issuance.
- Beneficial Ownership Limitation: Warrant exercise is limited to prevent holders from owning more than 4.99% (or 9.99% at election) of outstanding shares.
Note: This filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity positions.
Material Changes
The primary material change is the increase in outstanding equity and potential dilution resulting from the Registered Offering and concurrent Private Placement. The company entered into a Securities Purchase Agreement and a Placement Agency Agreement on April 6, 2018.
Outlook, Risks, and Unusual Items
- Offering Structure: The transaction involved a registered offering under an effective Form S-3 and a concurrent private placement for warrants exempt under Section 4(a)(2) and Rule 506(b).
- Use of Proceeds: The filing text does not specify the intended use of the net proceeds.
- Risks: Standard risks associated with equity dilution and the beneficial ownership limitations on warrant exercise.
Investor Verification Checklist
- Verify the final net proceeds after deducting the 8% placement fee and offering expenses.
- Confirm the exact number of shares outstanding post-closing to assess the dilution impact of the 900,000 new shares and 900,000 warrants.
- Review the attached Securities Purchase Agreement (Exhibit 10.1) for specific covenants or conditions.
- Check subsequent filings for the actual use of proceeds and any impact on the company's cash position.